logo-loader
viewValiRx PLC

ValiRx monitors working capital position amid talks to end subscription agreement with investor

ValiRX said it expects to announce the outcome of talks with European High Growth “shortly” and no longer intends to enter into further arrangements with the investor.

prostate cancer
The investment would have helped fund the Phase II trial of ValiRx's prostate cancer drug

ValiRx Plc (LON:VAL) said it is carefully monitoring its working capital position as advanced talks to terminate a subscription agreement with European High Growth Opportunities Securitisation Fund continue.

In late April, European High Growth agreed to subscribe for a total of 213mln shares in ValiRX at a price of 0.6p each, raising gross proceeds of £1.28mln.

READ: ValiRx secures cash to fund VAL201 trial through to completion

The money was to be drawn down in three equal tranches of £426,000, which would have helped fund the Phase II trial of ValiRx's prostate cancer drug, VAL201, through to completion.

However, last month ValiRX said it was in advanced discussions to terminate the agreement following a delay to the issue of Tranche 2 shares, and enter into a new convertible bond facility with the investor. 

READ: ValiRx in talks to terminate subscription agreement and enter into a new convertible bond facility

The biotechnology company on Monday said it expects to announce the outcome of talks with European High Growth “shortly” and no longer intends to enter into further arrangements with the investor.

ValiRx added that it understands that European High Growth no longer has a holding in the company.

The group’s working capital position is dependent on new funds being raised in the short term so it has arranged to dispose of its investment in an unlisted security for £140,000. The proceeds are expected to be received in the next week.

ValiRx is also due to receive a £400,000 payment form the HMRC in July for a research and development tax credit.

“The directors will continue to monitor the company's working capital position and will make further announcements as necessary,” it said.

Quick facts: ValiRx PLC

Price: 0.125 GBX

AIM:VAL
Market: AIM
Market Cap: £1.67 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ValiRx PLC named herein, including the promotion by the Company of ValiRx PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: Green light for ValiRx to increase dose of VAL201

Top stories from the Proactive Investors UK newsroom. ValirX (LON:VAL) has received a boost for its prostate cancer treatment VAL201 after UK regulators approved a substantial increase in the doses allowed in future clinical trials. The phase I/II trial so far has met all primary and...

on 20/6/19

RNS

Holding(s) in Company

5 days, 15 hours ago

Appointment of Joint Broker

5 days, 20 hours ago

Holding(s) in Company

1 week, 1 day ago

Half-year Report

on 26/9/19

Company Update

on 24/9/19

2 min read